• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


All the latest conference updates; those that we are attending and the studies that we are presenting

The 21st Annual Conference will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers, including how industry is working to overcome the challenges of opioid-based treatment.

Transpharmation will be hosting round table talks on both days. Inflammation Pain Lead Ana Pereira will be discussing Translational endpoints for Preclinical Pain at 1pm on 10th May, Neuropathic Pain Lead Daniel Cohn will be discussing Novel Pharmacological approach in Pain Therapy at 11.20am on 11th May. We are also hosting ‘meet the team’ sessions at 11.20am and 4.30pm on the 10th May and 1.35pm on the 11th May. We hope to see you there.

To view our presentation click here https://youtu.be/eqM1_l8-sEI


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design